• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Indolizines

1-Indolizinecarboxylic acid ethyl ester (CAS No. 93476-46-1): A Key Intermediate in Modern Pharmaceutical Research

The compound 1-Indolizinecarboxylic acid ethyl ester (CAS No. 93476-46-1) represents a significant intermediate in the realm of pharmaceutical chemistry, playing a pivotal role in the synthesis of various bioactive molecules. Its unique structural framework, combining an indolizine core with a carboxylic acid ethyl ester functionality, makes it a versatile building block for medicinal chemists exploring novel therapeutic agents.

Indolizine derivatives have garnered considerable attention in recent years due to their diverse pharmacological properties. These compounds exhibit potential applications across multiple therapeutic areas, including central nervous system disorders, anti-inflammatory treatments, and anticancer strategies. The ethyl ester moiety in 1-Indolizinecarboxylic acid ethyl ester not only enhances solubility but also provides a reactive site for further functionalization, enabling the development of structurally diverse analogs.

Recent advancements in synthetic methodologies have further highlighted the utility of this compound. Researchers have leveraged palladium-catalyzed cross-coupling reactions to introduce various substituents at the indolizine scaffold, thereby expanding the chemical space for drug discovery. Additionally, the ester group has been utilized in peptide mimetics and prodrug formulations, underscoring its importance in designing biologically active molecules with improved pharmacokinetic profiles.

The pharmaceutical industry has been particularly interested in 1-Indolizinecarboxylic acid ethyl ester for its role in developing small-molecule inhibitors targeting enzyme-mediated pathways. For instance, studies have demonstrated its applicability in synthesizing inhibitors of cyclin-dependent kinases (CDKs), which are critical regulators of cell cycle progression and implicated in various cancers. The indolizine core’s ability to interact with aromatic pockets in protein targets has been exploited to enhance binding affinity and selectivity.

In the context of drug development pipelines, 1-Indolizinecarboxylic acid ethyl ester serves as a precursor for more complex scaffolds through ring-closing metathesis or intramolecular cyclization reactions. These transformations have enabled the synthesis of polycyclic structures that mimic natural product architectures, which are often associated with high biological activity. Such derivatives are being evaluated for their potential as kinase inhibitors, protease inhibitors, and even as modulators of G-protein coupled receptors.

The growing interest in 1-Indolizinecarboxylic acid ethyl ester is also reflected in its incorporation into clinical trials. Several research groups have reported promising preclinical data supporting its use as a lead compound or key intermediate in novel drug candidates. These studies underscore the compound’s significance not only as a synthetic intermediate but also as a potential therapeutic agent itself.

From a chemical biology perspective, 1-Indolizinecarboxylic acid ethyl ester has been employed to probe enzyme mechanisms and develop enzyme probes for biochemical assays. Its structural features allow it to serve as a scaffold for designing molecules that can selectively label or inhibit specific enzymes, facilitating the study of metabolic pathways and disease mechanisms at the molecular level.

The synthesis of 1-Indolizinecarboxylic acid ethyl ester itself presents an interesting challenge due to its complex structural motif. Modern synthetic approaches often involve multi-step sequences starting from readily available precursors such as indole or benzene derivatives. Advances in flow chemistry have also enabled more efficient and scalable production methods for this compound, reducing reaction times and improving yields.

Looking ahead, the future prospects for 1-Indolizinecarboxylic acid ethyl ester are promising, with ongoing research exploring its applications in areas such as antibiotic development and antiviral therapies. The compound’s unique structural features make it an attractive candidate for designing molecules that can interact with viral proteases or other essential viral enzymes, offering new avenues for antiviral drug discovery.

In conclusion,1-Indolizinecarboxylic acid ethyl ester (CAS No. 93476-46-1) stands out as a versatile and valuable intermediate in pharmaceutical research. Its broad applicability across multiple therapeutic areas, coupled with recent advancements in synthetic methodologies and drug discovery technologies, positions it as a cornerstone molecule for future innovations in medicinal chemistry.

• 207791-84-2(2-methyl-6-Indolizinecarboxylic acid methyl ester)
• 22320-28-1(2-methyl-6-Indolizinecarboxylic acid ethyl ester)
• 153274-63-6(2-Indolizinecarboxylicacid, ethyl ester)
• 649727-13-9(1H-Pyrrole-3-carboxylic acid, 1-(8-quinolinyl)-, methyl ester)
• 66182-01-2(Ethyl indolizine-6-carboxylate)
• 76577-82-7(Pyrrolo[1,2-a]quinoline-2-carboxylic acid ethyl ester)
• 316375-85-6(Indolizine-1-carboxylic Acid Methyl Ester)
• 14174-98-2(Diethyl 1,2-Indolizinedicarboxylate)
• 1126444-01-6(1-Indolizinecarboxylic acid 2-propen-1-yl ester)
• 16959-62-9(methyl indolizine-2-carboxylate)